Trials of Russian vaccine Sputnik V to be carried out in India
New Delhi, Oct 17 (Prensa Latina) Russian vaccine candidate, Sputnik V, will undergo phase three trials in India after receiving approval from the central drug control authority, it was disclosed here today.
Sputnik V, the first registered vaccine in the world, will have a multicenter, randomized controlled study, which includes safety and immunogenicity analysis, said a statement from the Russian Direct Investment Fund and Reddys Laboratories Limited, The Week magazine reflected here.
In early September, Reddy and the Russian Fund for Direct Investment partnered to carry out clinical trials of the Sputnik V vaccine and its subsequent distribution in India.
The agreement will supply 100 million doses of the vaccine to India.
Sputnik V is currently passing phase three of the clinical trial in Russia with 40 thousand volunteers. Clinical trials at that level for the Russian vaccine also began in the United Arab Emirates last week, in addition to those in Belarus and Venezuela.
On August 11, the first Russian vaccine for Covid-19, based on the platform for human adenoviral vectors and developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, was registered by the Russian Ministry of Health.
|By the minute||Most read|